查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830981

单株抗体治疗（mAB）市场

Monoclonal Antibody Therapeutics (mABs) Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

预计单株抗体疗法 (mAB) 市场规模将从 2024 年的 2.4914 亿美元扩大到 2031 年的 6.196 亿美元，2025 年至 2031 年的预估复合年增长率为 13.9%。

市场洞察与分析师观点：密集的研究和开发工作以及慢性病发病率的上升预计将对未来几年单株抗体疗法 (mAB) 市场的预测产生重大影响。

单株抗体 (mAb) 是一类特异性靶向特定抗原的统一抗体集合。治疗性 mAb 的生产需要哺乳动物表达系统，该系统提供糖基化、正确折迭、定向和抗体肽链共价结合所需的细胞机制，产生完整且具有生物活性的分子。双特异性抗体和三特异性抗体等创新抗体模式可以辨识单一抗原上的多个表位，而单域抗体则更容易穿透组织。这些先进的抗体类型可以提高抗体治疗的疗效，从而拓宽其应用领域。此外，这些抗体可以形成抗体-药物偶联物，增强化疗药物对特定细胞类型的标靶效率。基于 mAb 的药物在各种疾病中的生产正在推动市场成长。製造商的策略性产品发布为市场带来了丰厚的利润。此外，包含 mAb 的复方药物趋势在 mAb 治疗市场中日益兴起。

市场驱动因素

基于单株抗体（mAB）的多种疾病药物产量增长单株抗体疗法（mAB）用于治疗多种疾病，包括癌症、自体免疫疾病和代谢性疾病。这些由生物製药公司和研究机构开发的药物因其高特异性、有效的标靶能力以及极低的毒性和副作用，在全球市场上引起了广泛关注。因此，mAB疗法产能的提升预计将推动单株抗体疗法（mAB）市场的成长。

市场机会

透过製造商的策略发展推出创新产品

透过治疗性单株抗体（mAB）製造商的产品上市，有机成长有望在不久的将来增强单株抗体治疗（mAB）市场。 2022年3月，Adagio Therapeutics, Inc.宣布推出ADG20 (ADINTREVIMAB)，这是首个在COVID-19暴露前和暴露后预防及治疗方面均达到具有统计学意义的主要终点的单克隆抗体，目前正在申请美国紧急使用授权（EUA）。

此外，透过併购实现的无机成长预计将带来新型治疗性单株抗体（mAB）的推出。例如，2023年7月，礼来公司宣布收购Versanis，这是一家专注于治疗心臟代谢疾病的私人临床阶段生物製药公司。此次收购使礼来公司能够获得Versanis的核心产品组合，其中包括一款名为bimagrumab的单克隆抗体产品，该产品目前正在进行“BELIEVE 2b期临床研究”，旨在评估其作为独立疗法以及与司美格鲁肽联合用药在减少脂肪量、保持肌肉量以及改善肥胖及相关并发症患者预后的潜力。预计这些因素将在未来几年显着促进单株抗体治疗（mAB）市场的成长。

单株抗体治疗（mAB）市场趋势

以单株抗体 (mAB) 为特色的组合药物：根据美国国立卫生研究院 (NIH) 2021 年的报告，罗氏和再生元（製药公司）启动了一项 2/3 期临床试验，以评估组合单株抗体对轻度至中度 COVID-19 患者的效果。他们正在评估“REGN-COV2”，这是一种结合两种单株抗体（casirivimab 和 imdevimab）的鸡尾酒疗法，用于治疗 COVID-19。两家公司预计，这种组合单株抗体药物可将住院率降低 70%，并且对 12 岁以上（体重超过 40 公斤）的儿童尤其有效。研究人员正在积极探索更多单株抗体的治疗组合。例如，礼来公司开发的 bamlanivimab 和 etesevimab 在 2022 年对 COVID-19 表现出了积极的临床效果。因此，利用单株抗体治疗各种疾病的联合用药趋势预计将在未来几年在单株抗体疗法 (mAB) 市场中获得显着的吸引力。

战略洞察

报告细分和范围：单株抗体疗法（mAB）市场的分析是透过考虑以下细分进行的：产品、应用和配销通路。

依产品类型，市场分为重组单株抗体 (mAB)、抗体-药物偶联物、双特异性和多特异性单株抗体、生物相似药及其他。按应用类型，单株抗体治疗 (mAB) 市场细分为肿瘤学、自体免疫疾病及其他。自体免疫疾病细分市场进一步细分为类风湿性关节炎、牛皮癣、溃疡性结肠炎及其他。配销通路细分，包括医院药房、零售药房及其他。

就产品而言，重组单株抗体 (mAB) 领域在 2022 年占据了单株抗体治疗 (mAB) 市场的最大份额。预计抗体-药物偶联物领域在预测期内的复合年增长率最快，为 18.5%。根据 ACS Publications 的报告，治疗性重组单株抗体代表了尖端生物医学研究，旨在开发有效的策略来治疗目前尚无有效治疗方法的多种疾病。托珠单抗是一种重组单株抗体，用于治疗关节炎、特发性关节炎和类风湿性关节炎 (RA)。此外，重组单株抗体也可用于治疗自体免疫疾病和癌症。贝伐单抗是一种重组单株抗体，目前用于治疗乳癌、肺癌和大肠癌，以及 HIV-1、细菌毒素感染/反应以及 SARS-CoV-2 和伊波拉病毒感染。

抗体药物偶联物 (ADC) 是一类快速崛起的治疗药物，它将化疗和免疫疗法结合起来。根据美国国立卫生研究院 (NIH) 的报告，ADC 主要基于免疫球蛋白 G (IgG)，迄今已有 13 种 ADC 获得美国食品药物管理局 (FDA) 的批准。此外，目前有超过 90 种 ADC 正在处于临床开发或试验阶段。

序号产品（已核准的 ADC）疾病适应症1

麦洛塔尔

復发性急性骨髓性白血病

2

阿德塞特里斯

復发性霍奇金淋巴瘤和復发性系统性间变性大细胞淋巴瘤

3

卡德西拉

HER2阳性转移性乳癌

4

贝斯蓬萨

復发或难治性CD22阳性B细胞前驱急性淋巴性白血病

5

鲁莫西提

復发或难治性毛细胞白血病或HCL

6

波利维

復发或难治性（R/R）瀰漫大B细胞淋巴瘤或DLBCL

7

帕德切夫

转移性尿路上皮癌

8

恩赫图

转移性 HER2 阳性乳癌

9

特罗德尔维

转移性三阴性乳癌

10

布伦雷普

復发或难治性多发性骨髓瘤

11

兹尼洛塔

大B细胞淋巴瘤

12

蒂夫达克

復发性或转移性子宫颈癌治疗

十三

埃拉希尔

铂类抗药性卵巢癌

来源：单次使用支援文章

因此，预计 ADC 的监管批准和针对罕见疾病治疗策略的正在进行的临床试验将推动单株抗体疗法 (mAB) 市场的成长，特别是在预测期内的抗体-药物偶联物领域。

区域分析：从地理上讲，单株抗体治疗 (mAB) 市场报告涵盖北美、欧洲、亚太地区、中东和非洲以及南美和中美。 2022 年，北美在全球单株抗体治疗 (mAB) 市场中占有最大份额。预计亚太地区在 2022 年至 2030 年期间的复合年增长率最高。在北美，美国占最大的市场份额，受益于 mAB 治疗药物的快速产品审批流程。根据发表在《BioMed Central》杂誌上的一项研究，截至 2019 年 12 月，美国 FDA 已批准 79 种治疗性 mAB。其中，30 种用于癌症治疗。 2021 年 5 月，FDA 批准了一种新的治疗性 mAB-Sotrovimab 的 EUA，该药物旨在用于治疗重症 COVID-19 患者的门诊治疗。 2022年2月，FDA为礼来公司开发的针对Omicron变体的bebtelovimab颁发了紧急使用授权（EUA）。此外，etesevimab也是美国FDA核准的治疗性单株抗体药物之一。

单株抗体治疗 (mAB) 市场报告范围：产业发展与未来机会：单株抗体治疗 (mAB) 市场主要参与者的几项策略倡议概述如下：

2023年1月，阿斯特捷利康的Evusheld在欧盟获得批准。 Evusheld是两种长效抗体－替吉奥维马单抗（Tixagevimab，AZD8895）和西加维马单抗（Cilgavimab，AZD1061）的组合。美国政府透过美国卫生与公众服务部、战略防范与因应管理局（SRA）和生物医学高级研究与发展管理局（BARDA）的联邦资金支持该产品的开发。 2023年8月，再生元製药公司（Regeneron Pharmaceuticals, Inc.）与生物医学高级研究与发展管理局（BARDA）达成协议，以促进针对COVID-19的下一代单株抗体疗法的临床开发、生产和监管许可。根据该协议，再生元计划与生物医学高级研究与发展局 (BARDA) 合作，评估、进一步开发和生产该疗法，并开展监管活动。竞争格局和主要公司：单株抗体疗法 (mAB) 市场的知名公司包括葛兰素史克、罗氏製药、拜耳、安进、诺华、艾伯维、百时美施贵宝、杨森製药、默克和阿斯特捷利康。单株抗体疗法 (mAB) 市场报告包含公司定位和集中度分析，以评估市场主要参与者的表现。

目录

第一章：简介

第 2 章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：单株抗体治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：单株抗体治疗市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：单株抗体治疗市场－全球市场分析

  • 单株抗体治疗－全球市场概览
  • 单株抗体治疗－全球市场及2030年预测

第七章：单株抗体治疗市场-收入分析-依产品，2020-2030

  • 概述
  • 重组单株抗体（mAB）
  • 抗体-药物偶联物
  • 双-多特异性单株抗体（mAB）
  • 生物相似药
  • 其他的

第 8 章：单株抗体治疗市场 - 收入分析 - 按应用，2020-2030 年

  • 概述
  • 癌症
  • 自体免疫疾病
  • 其他的

第九章：单株抗体治疗市场-收入分析-按配销通路，2020-2030年

  • 概述
  • 医院药房
  • 零售药局
  • 其他的

第 10 章：单株抗体治疗市场 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 13 章：单株抗体治疗市场 - 关键公司简介

  • F. Hoffmann-La-Roche
  • AstraZeneca
  • Bayer AG
  • Merck KGaA
  • GlaxoSmithKline plc
  • Amgen
  • Novartis AG
  • AbbVie Inc.
  • Janssen Pharmaceuticals
  • Bristol-Myers Squibb Company

第 14 章：附录

简介目录
Product Code: TIPRE00003417

The market for monoclonal antibody therapeutics (mABs) is anticipated to expand from US$ 249.14 million in 2024 to US$ 619.6 million by 2031, reflecting a projected CAGR of 13.9% from 2025 to 2031.

Market Insights and Analyst Perspective:Intensive research and development efforts, along with a rising incidence of chronic diseases, are expected to significantly influence the forecast for the monoclonal antibody therapeutics (mABs) market in the upcoming years.

A monoclonal antibody (mAbs) is a uniform collection of antibodies that specifically target designated antigens. The manufacturing of therapeutic mAbs necessitates a mammalian expression system that provides the cellular machinery required for glycosylation, proper folding, orientation, and covalent binding of antibody peptide chains to create complete and biologically active molecules. Innovative antibody modalities, such as bispecific and trispecific antibodies, can recognize multiple epitopes on a single antigen, while single-domain antibodies can more easily penetrate tissues. These advanced antibody types can improve the efficacy of antibody therapeutics, thereby broadening their application areas. Additionally, these antibodies can form antibody-drug conjugates to enhance the targeting efficiency of chemotherapy agents towards specific cell types. The production of mAB-based drugs for various diseases is driving market growth. Strategic product launches by manufacturers present lucrative opportunities in the market. Moreover, the trend of combination drugs that include mABs is gaining traction in the mAbs therapeutic market.

Market Driver

Growth in Production of mAB-Based Drugs for Various Diseases

Monoclonal antibody therapeutics (mABs) are utilized to treat a diverse array of diseases, including cancer, autoimmune disorders, and metabolic conditions. These drugs, developed by biopharmaceutical companies and research institutions, have garnered significant attention in the global market due to their high specificity, effective targeting capabilities, and minimal toxicity and side effects. Consequently, an increase in the production capacity of mAB therapeutics is expected to propel the growth of the monoclonal antibody therapeutics (mABs) market.

Market Opportunity

Innovative Product Launches Through Strategic Developments by Manufacturers

Organic growth through product launches by manufacturers of therapeutic mABs is likely to enhance the monoclonal antibody therapeutics (mABs) market in the near future. In March 2022, Adagio Therapeutics, Inc. announced the launch of ADG20 (ADINTREVIMAB), the first monoclonal antibody to achieve primary endpoints with statistical significance for both pre-and post-exposure prophylaxis and treatment of COVID-19, seeking US Emergency Use Authorization (EUA).

Additionally, inorganic growth through mergers and acquisitions is expected to lead to the introduction of new therapeutic mABs. For example, in July 2023, Eli Lilly announced the acquisition of Versanis, a private clinical-stage biopharmaceutical company focused on treating cardiometabolic diseases. This acquisition allows Eli Lilly to access Versanis's core product portfolio, which includes a monoclonal antibody product named bimagrumab, currently being evaluated in the "BELIEVE Phase 2b study" as a standalone treatment and in combination with semaglutide for its potential to reduce fat mass, preserve muscle mass, and improve outcomes for individuals with obesity and related complications. These factors are anticipated to significantly contribute to the growth of the monoclonal antibody therapeutics (mABs) market in the coming years.

Monoclonal Antibody Therapeutics (mABs) Market Trends

Combination Drugs Featuring Monoclonal Antibodies (mABs)As per the National Institute of Health (NIH) 2021 report, Roche and Regeneron (pharmaceutical companies) initiated a phase 2/3 clinical trial to assess combination monoclonal antibodies for patients with mild to moderate COVID-19. They are evaluating "REGN-COV2," a cocktail drug that combines two monoclonal antibodies-casirivimab and imdevimab-for COVID-19 treatment. These companies anticipate that this combination mAB drug could reduce hospitalization by 70% and be particularly effective for children over 12 years old (weighing more than 40 kg). Researchers are actively exploring more therapeutic combinations of monoclonal antibodies. For instance, bamlanivimab and etesevimab developed by Eli Lilly demonstrated positive clinical outcomes for COVID-19 in 2022. Therefore, the trend of combination drugs utilizing monoclonal antibodies for various diseases is expected to gain significant traction in the monoclonal antibody therapeutics (mABs) market in the coming years.

Strategic Insights

Report Segmentation and Scope:The analysis of the monoclonal antibody therapeutics (mABs) market has been conducted by considering the following segments: product, application, and distribution channel.

The market is categorized by product into recombinant mABs, antibody-drug conjugates, bispecific and multispecific mABs, biosimilars, and others. By application, the monoclonal antibody therapeutics (mABs) market is segmented into oncology, autoimmune diseases, and others. The autoimmune diseases segment is further divided into rheumatoid arthritis, psoriasis, ulcerative colitis, and others. The distribution channel segmentation includes hospital pharmacies, retail pharmacies, and others.

In terms of product, the recombinant mABs segment held the largest share of the monoclonal antibody therapeutics (mABs) market in 2022. The antibody-drug conjugates segment is projected to exhibit the fastest CAGR of 18.5% during the forecast period. According to a report by ACS Publications, therapeutic recombinant monoclonal antibodies represent cutting-edge biomedical research aimed at developing effective strategies to treat a wide range of diseases for which no effective treatments currently exist. Tocilizumab is an example of a recombinant mAB used to treat arthritis, idiopathic arthritis, and rheumatoid arthritis (RA). Furthermore, recombinant mABs can also be utilized for treating autoimmune diseases and cancer. Bevacizumab is a recombinant mAB currently employed in the treatment of breast, lung, and colorectal cancers, as well as HIV-1, bacterial toxin infections/reactions, and infections from SARS-CoV-2 and the Ebola virus.

Antibody-drug conjugates (ADCs) are a rapidly emerging class of therapeutic agents that combine chemotherapy and immunotherapy. According to a NIH report, ADCs are primarily based on immunoglobulin G (IgG), with 13 ADCs having received approval from the US Food and Drug Administration (FDA) to date. Additionally, over 90 ADCs are currently in clinical development or trials.

Thus, the regulatory approvals of ADCs and ongoing clinical trials for treatment strategies targeting rare diseases are expected to drive the growth of the monoclonal antibody therapeutics (mABs) market, particularly in the antibody-drug conjugates segment during the forecast period.

Regional Analysis:Geographically, the Monoclonal Antibody Therapeutics (mABs) market report encompasses North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. In 2022, North America held the largest share of the global monoclonal antibody therapeutics (mABs) market. The Asia Pacific region is projected to experience the highest CAGR from 2022 to 2030. Within North America, the US represents the largest market share, benefiting from expedited product approval processes for mAB therapeutics. As of December 2019, 79 therapeutic mABs had been approved by the US FDA, according to a study published in the BioMed Central journal. Among these, 30 are intended for cancer treatment. In May 2021, the FDA granted EUA for a new therapeutic mAB-Sotrovimab-designed for outpatient use in treating individuals with severe COVID-19. In February 2022, the FDA issued EUA for bebtelovimab, developed by Eli Lilly and Company, targeting the Omicron variant. Additionally, etesevimab is another example of therapeutic mABs approved by the US FDA.

Monoclonal Antibody Therapeutics (mABs) Market Report Scope: Industry Developments and Future Opportunities:Several strategic initiatives by leading players in the monoclonal antibody therapeutics (mABs) market are outlined below:

In January 2023, AstraZeneca received approval for Evusheld in the European Union (EU). Evusheld is a combination of two long-acting antibodies-tixagevimab (AZD8895) and cilgavimab (AZD1061). The US government supported the development of this product through federal funding from the Department of Health and Human Services, the Administration for Strategic Preparedness and Response, and the Biomedical Advanced Research and Development Authority.

In August 2023, Regeneron Pharmaceuticals, Inc. entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to facilitate clinical development, manufacturing, and regulatory licensure for next-generation monoclonal antibody therapy against COVID-19. Under this agreement, Regeneron aims to collaborate with BARDA to evaluate, further develop, and manufacture this therapy, as well as conduct regulatory activities.

Competitive Landscape and Key Companies:Prominent companies in the monoclonal antibody therapeutics (mABs) market include GlaxoSmithKline, F. Hoffmann-La Roche, Bayer AG, Amgen, Novartis, AbbVie, Bristol-Myers Squibb, Janssen Pharmaceutical, Merck KGaA, and AstraZeneca. The monoclonal antibody therapeutics (mABs) market report includes an analysis of company positioning and concentration to assess the performance of key players in the market.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Monoclonal Antibody Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Monoclonal Antibody Therapeutics Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Monoclonal Antibody Therapeutics Market - Global Market Analysis

  • 6.1 Monoclonal Antibody Therapeutics - Global Market Overview
  • 6.2 Monoclonal Antibody Therapeutics - Global Market and Forecast to 2030

7. Monoclonal Antibody Therapeutics Market - Revenue Analysis (USD Million) - By Product, 2020-2030

  • 7.1 Overview
  • 7.2 Recombinant Monoclonal Antibodies (mABs)
  • 7.3 Antibody-Drug Conjugates
  • 7.4 Bi-Multi Specific Monoclonal Antibodies (mABs)
  • 7.5 Biosimilars
  • 7.6 Others

8. Monoclonal Antibody Therapeutics Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 8.1 Overview
  • 8.2 Cancer
  • 8.3 Autoimmune Diseases
    • 8.3.1 Rheumatoid Arthritis (RA)
    • 8.3.2 Psoriasis
    • 8.3.3 Ulcerative Colitis
    • 8.3.4 Others
  • 8.4 Others

9. Monoclonal Antibody Therapeutics Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Others

10. Monoclonal Antibody Therapeutics Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Monoclonal Antibody Therapeutics Market Overview
    • 10.1.2 North America Monoclonal Antibody Therapeutics Market Revenue and Forecasts to 2030
    • 10.1.3 North America Monoclonal Antibody Therapeutics Market Revenue and Forecasts and Analysis - By Product
    • 10.1.4 North America Monoclonal Antibody Therapeutics Market Revenue and Forecasts and Analysis - By Application
    • 10.1.5 North America Monoclonal Antibody Therapeutics Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Monoclonal Antibody Therapeutics Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Monoclonal Antibody Therapeutics Market
        • 10.1.6.1.1 United States Monoclonal Antibody Therapeutics Market, by Product
        • 10.1.6.1.2 United States Monoclonal Antibody Therapeutics Market, by Application
        • 10.1.6.1.3 United States Monoclonal Antibody Therapeutics Market, by Distribution Channel
      • 10.1.6.2 Canada Monoclonal Antibody Therapeutics Market
        • 10.1.6.2.1 Canada Monoclonal Antibody Therapeutics Market, by Product
        • 10.1.6.2.2 Canada Monoclonal Antibody Therapeutics Market, by Application
        • 10.1.6.2.3 Canada Monoclonal Antibody Therapeutics Market, by Distribution Channel
      • 10.1.6.3 Mexico Monoclonal Antibody Therapeutics Market
        • 10.1.6.3.1 Mexico Monoclonal Antibody Therapeutics Market, by Product
        • 10.1.6.3.2 Mexico Monoclonal Antibody Therapeutics Market, by Application
        • 10.1.6.3.3 Mexico Monoclonal Antibody Therapeutics Market, by Distribution Channel
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Monoclonal Antibody Therapeutics Market - Key Company Profiles

  • 13.1 F. Hoffmann-La-Roche
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 AstraZeneca
  • 13.3 Bayer AG
  • 13.4 Merck KGaA
  • 13.5 GlaxoSmithKline plc
  • 13.6 Amgen
  • 13.7 Novartis AG
  • 13.8 AbbVie Inc.
  • 13.9 Janssen Pharmaceuticals
  • 13.10 Bristol-Myers Squibb Company

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud